Reply To: Traders Market Weekly: Treasury Debt and Central Bank Balancing Act

#68535
Truman
Participant

AbbVie (ABBV 145.70, -0.68, -0.5%): confirms it will acquire Cerevel Therapeutics (CERE) for $45.00/share in cash; total equity value of approximately $8.7 bln; to be accretive to EPS in 2030